7h
Dealbreaker on MSNCash-Strapped Gene Therapy Firm Bluebird Bio Agrees to Acquisition by Private EquityCarlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird Bio for about $29 million.
Bluebird bio (BLUE) shares continued their downward descent Monday following news that the company plans to be taken private through a deal valued at up to $96M. Read more here.
NSM Insurance Group announced it has signed a definitive agreement to sell its U.S. commercial insurance division to New Mountain Capital, a ...
The last week of February has spirits rising along with the temperatures. Telemiracle Week is on until March 1 with the ...
12 years after going public, beleaguered gene therapy company bluebird bio will be sold to private equity groups Carlyle and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results